These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 3047432)

  • 21. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.
    Prince GA; Hemming VG; Horswood RL; Chanock RM
    Virus Res; 1985 Oct; 3(3):193-206. PubMed ID: 3907188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.
    Collins PL; Purcell RH; London WT; Lawrence LA; Chanock RM; Murphy BR
    Vaccine; 1990 Apr; 8(2):164-8. PubMed ID: 2336876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage.
    Anderson K; Stott EJ; Wertz GW
    J Gen Virol; 1992 May; 73 ( Pt 5)():1177-88. PubMed ID: 1375280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.
    Stott EJ; Ball LA; Young KK; Furze J; Wertz GW
    J Virol; 1986 Nov; 60(2):607-13. PubMed ID: 3773052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins.
    García-Barreno B; Palomo C; Peñas C; Delgado T; Perez-Breña P; Melero JA
    J Virol; 1989 Feb; 63(2):925-32. PubMed ID: 2463385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections.
    Muelenaer PM; Henderson FW; Hemming VG; Walsh EE; Anderson LJ; Prince GA; Murphy BR
    J Infect Dis; 1991 Jul; 164(1):15-21. PubMed ID: 2056202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.
    Bukreyev A; Yang L; Fricke J; Cheng L; Ward JM; Murphy BR; Collins PL
    J Virol; 2008 Dec; 82(24):12191-204. PubMed ID: 18842713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
    Spriggs MK; Murphy BR; Prince GA; Olmsted RA; Collins PL
    J Virol; 1987 Nov; 61(11):3416-23. PubMed ID: 2822951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.
    Connors M; Collins PL; Firestone CY; Murphy BR
    J Virol; 1991 Mar; 65(3):1634-7. PubMed ID: 1995956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections.
    Wagner DK; Muelenaer P; Henderson FW; Snyder MH; Reimer CB; Walsh EE; Anderson LJ; Nelson DL; Murphy BR
    J Clin Microbiol; 1989 Mar; 27(3):589-92. PubMed ID: 2715331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection.
    Trudel M; Stott EJ; Taylor G; Oth D; Mercier G; Nadon F; Séguin C; Simard C; Lacroix M
    Arch Virol; 1991; 117(1-2):59-71. PubMed ID: 1706591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication.
    Nicholas JA; Rubino KL; Levely ME; Meyer AL; Collins PL
    Virology; 1991 Jun; 182(2):664-72. PubMed ID: 2024493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of breast feeding on the development of anti-idiotype antibody response to F glycoprotein of respiratory syncytial virus in infant mice after post-partum maternal immunization.
    Okamoto Y; Tsutsumi H; Kumar NS; Ogra PL
    J Immunol; 1989 Apr; 142(7):2507-12. PubMed ID: 2926142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.
    Bembridge GP; Lopez JA; Cook R; Melero JA; Taylor G
    J Virol; 1998 May; 72(5):4080-7. PubMed ID: 9557697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R; Latimer L; Gomis S; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2019 Feb; 162():54-60. PubMed ID: 30550799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.
    Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G
    J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.